| Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 6774 | 2011 |
| Inhibition of mutated, activated BRAF in metastatic melanoma KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ... New England Journal of Medicine 363 (9), 809-819, 2010 | 3430 | 2010 |
| Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532, 2015 | 3190 | 2015 |
| Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... New England Journal of Medicine 369 (2), 134-144, 2013 | 2939 | 2013 |
| PD-1 blockade induces responses by inhibiting adaptive immune resistance PC Tumeh, CL Harview, JH Yearley, IP Shintaku, EJM Taylor, L Robert, ... Nature 515 (7528), 568, 2014 | 2812 | 2014 |
| Genetic basis for clinical response to CTLA-4 blockade in melanoma A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ... New England Journal of Medicine 371 (23), 2189-2199, 2014 | 2378 | 2014 |
| Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles ME Davis, JE Zuckerman, CHJ Choi, D Seligson, A Tolcher, CA Alabi, ... Nature 464 (7291), 1067, 2010 | 2234 | 2010 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 1989 | 2012 |
| Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation R Nazarian, H Shi, Q Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ... Nature 468 (7326), 973, 2010 | 1899 | 2010 |
| Improved overall survival in melanoma with combined dabrafenib and trametinib C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ... New England Journal of Medicine 372 (1), 30-39, 2015 | 1547 | 2015 |
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ... Nature 467 (7315), 596, 2010 | 1512 | 2010 |
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ... The Lancet 384 (9948), 1109-1117, 2014 | 1405 | 2014 |
| Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ... New England Journal of Medicine 371 (20), 1867-1876, 2014 | 1366 | 2014 |
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ... Nature 487 (7408), 500, 2012 | 1366 | 2012 |
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387, 2011 | 1167 | 2011 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 1126 | 2014 |
| Mutations associated with acquired resistance to PD-1 blockade in melanoma JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ... New England Journal of Medicine 375 (9), 819-829, 2016 | 1059 | 2016 |
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015 | 1012 | 2015 |
| Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors TR Wilson, J Fridlyand, Y Yan, E Penuel, L Burton, E Chan, J Peng, E Lin, ... Nature 487 (7408), 505, 2012 | 987 | 2012 |
| RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ... New England Journal of Medicine 366 (3), 207-215, 2012 | 904 | 2012 |
